These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21903705)

  • 1. Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities.
    Kubota D; Orita H; Yoshida A; Gotoh M; Kanda T; Tsuda H; Hasegawa T; Katai H; Shimada Y; Kaneko K; Kawai A; Kondo T
    Jpn J Clin Oncol; 2011 Oct; 41(10):1194-202. PubMed ID: 21903705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities.
    Kikuta K; Gotoh M; Kanda T; Tochigi N; Shimoda T; Hasegawa T; Katai H; Shimada Y; Suehara Y; Kawai A; Hirohashi S; Kondo T
    Jpn J Clin Oncol; 2010 Jan; 40(1):60-72. PubMed ID: 19815537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation study on pfetin and ATP-dependent RNA helicase DDX39 as prognostic biomarkers in gastrointestinal stromal tumour.
    Kubota D; Okubo T; Saito T; Suehara Y; Yoshida A; Kikuta K; Tsuda H; Katai H; Shimada Y; Kaneko K; Kawai A; Kondo T
    Jpn J Clin Oncol; 2012 Aug; 42(8):730-41. PubMed ID: 22723667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of pfetin: a validation study in gastrointestinal stromal tumors using a commercially available antibody.
    Kubota D; Mukaihara K; Yoshida A; Suehara Y; Saito T; Okubo T; Gotoh M; Orita H; Tsuda H; Kaneko K; Kawai A; Kondo T; Sato K; Yao T
    Jpn J Clin Oncol; 2013 Jun; 43(6):669-75. PubMed ID: 23619989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics.
    Suehara Y; Kondo T; Seki K; Shibata T; Fujii K; Gotoh M; Hasegawa T; Shimada Y; Sasako M; Shimoda T; Kurosawa H; Beppu Y; Kawai A; Hirohashi S
    Clin Cancer Res; 2008 Mar; 14(6):1707-17. PubMed ID: 18347171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
    Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.
    Steinert DM; Oyarzo M; Wang X; Choi H; Thall PF; Medeiros LJ; Raymond AK; Benjamin RS; Zhang W; Trent JC
    Cancer; 2006 Apr; 106(7):1617-23. PubMed ID: 16518826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
    Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
    J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
    Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biomarker development by cancer proteomics].
    Kondo T
    Nihon Rinsho; 2012 May; 70(5):754-8. PubMed ID: 22619997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
    Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
    Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Roles of risk assessment and Ki-67 index in judging prognostic of gastrointestinal stromal tumors].
    Liang YM; Li XH; Chen W
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1041-5. PubMed ID: 18754437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    Shen L; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors.
    Rawnaq T; Kunkel M; Bachmann K; Simon R; Zander H; Brandl S; Sauter G; Izbicki JR; Kaifi JT
    Ann Surg Oncol; 2011 Feb; 18(2):559-65. PubMed ID: 20589434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities.
    Artinyan A; Kim J; Soriano P; Chow W; Bhatia S; Ellenhorn JD
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2194-201. PubMed ID: 18708414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
    Zhu J; Wang Y; Hou M; Li HY; Zhang J
    Oncology; 2007; 73(5-6):324-7. PubMed ID: 18497504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.